anti- FIP1L1 antibody

Size

2X100μg

Catalog no#

FNab03131

Price

320 EUR

Uniprot ID

Q6UN15

Calculated MW

75 kDa

Form

liquid

Synonyms

FIP1, RHE

French translation

anticorps

Specificity

Human, Mouse, Rat

Tested Application

ELISA, WB, IHC, IF

Purification

Immunogen affinity purified

Immunogen

FIP1 like 1 (S. cerevisiae)

Purity

≥95% as determined by SDS-PAGE

Recommended dilution

WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:50 - 1:100

Image1

Immunohistochemistry of paraffin-embedded human ovary tumor using FNab03131(FIP1L1 antibody) at dilution of 1:50

Storage

PBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20℃ for 24 months (Avoid repeated freeze / thaw cycles.)

Image4

K-562 cells were subjected to SDS PAGE followed by western blot with FNab03131(FIP1L1 antibody) at dilution of 1:1000

Properties

If you buy Antibodies supplied by FineTest they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.Antibody for research use.

Background

This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms.